Sector Expert: Daniel Pearlstein

M Partners

Image: Daniel Pearlstein

Daniel Pearlstein is an equity research analyst with M Partners covering the Life Sciences sector. His previous experience includes analyst roles at a North American healthcare venture capital firm, a medical device startup and a technology transfer incubator. Pearlstein holds a bachelor's degree in chemistry and a master's degree in management.



Recent Quotes

"CYNA finished Q2/15 with over $111M in cash; it is well capitalized."

— Daniel Pearlstein, M Partners (8/19/15)
more >

"Early data on BCT's BriaVax is encouraging, which should drive the stock to appreciate."

— Daniel Pearlstein, M Partners (7/23/15)
more >

"CYNA closed its U.S. offering on June 23, raising $72.5M."

— Daniel Pearlstein, M Partners (7/7/15)
more >

"The definitive agreement sets up BCT to prepare enough samples for use in Phase 1/2 trials in Q4/15."

— Daniel Pearlstein, M Partners (6/17/15)
more >

"We continue to like CTH as a play in the Parkinson's space."

— Daniel Pearlstein, M Partners (5/27/15)
more >

"Yesterday, CTH announced a $21M private placement at $0.95."

— Daniel Pearlstein, M Partners (4/1/15)
more >

"CTH intends to submit a 505(b)(2) NDA to the FDA in mid-late 2016."

— Daniel Pearlstein, M Partners (3/12/15)
more >

"The vote of confidence CTH has received from The Michael J. Fox Foundation is very advantageous."

The Life Sciences Report Interview with Daniel Pearlstein (1/8/15)
more >



Due to permission requirements, not all quotes are shown.